Zentalis Pharmaceuticals (ZNTL) Return on Sales (2024 - 2025)
Zentalis Pharmaceuticals' (ZNTL) quarterly Return on Sales came in at 0.06% in Q3 2025, down 1.0% year-on-year from 0.06% in Q3 2024, and up 8.27% quarter-over-quarter from 0.06% in Q2 2025.
Zentalis Pharmaceuticals (ZNTL) Return on Sales (2024 - 2025) Analysis & Trends
Zentalis Pharmaceuticals' Return on Sales history runs 2 years deep, the most recent figure standing at 0.06% for Q3 2025.
- On a quarterly basis, Return on Sales fell 1.0% year-over-year to 0.06% in Q3 2025; TTM through Sep 2025 was 0.06%, a 1.0% decrease from a year earlier, with the FY2024 full-year figure at 0.02%, changed N/A from the prior year.
- Return on Sales advanced to 0.06% in Q3 2025 per ZNTL's latest filing, from 0.06% in the prior quarter.
- Across five years, Return on Sales topped out at 0.0% in Q1 2024 and bottomed at 0.08% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 0.00% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zentalis Pharmaceuticals | 312.67 Mn | 312.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -0.06% |
| Jun 30, 2025 | -0.06% |
| Mar 31, 2025 | -0.08% |
| Dec 31, 2024 | -0.02% |
| Sep 30, 2024 | -0.04% |
| Jun 30, 2024 | -0.05% |
| Mar 31, 2024 | 0.00% |